The impact of confirmatory testing on the adoption of active surveillance for men with favorable-risk prostate cancer

Deborah Kaye*, Ji Qi, Todd Morgan, Susan Linsell, Ann Arbor, MI, Brian Lane, Grand Rapids, MI, James Montie, David Miller, Ann Arbor, MI, Michael Cher, Detroit, MI, for the Michigan Urological Surgery Improvement Collaborative, Ann Arbor, MI

INTRODUCTION AND OBJECTIVES: In the Michigan Urological Surgery Improvement Collaborative (MUSIC), we have promoted since 2016 a 6-month 'Consideration Phase' during which men with newly diagnosed favorable risk prostate cancer obtain confirmatory testing (e.g., repeat biopsy, prostate MRI and/or genomics) for more accurate risk classification. Herein, we examine the relationship between the use and results of confirmatory testing and the adoption of active surveillance (AS).

METHODS: We identified all men in the MUSIC registry who were diagnosed with favorable-risk prostate cancer (i.e., any Gleason 3+3 or low-volume Gleason 3+4) from 01/2016 through 02/2017. From this group, we examined trends in the use of confirmatory test(s) within 6 months from the diagnostic biopsy. We then compared the proportion of men remaining on AS 6 months after diagnosis according to the results of their confirmatory test(s) (i.e., reassuring vs non-reassuring). Last, we stratified the analyses by age <65 and >=65 years.

RESULTS: Among 2,455 patients with favorable-risk prostate cancer, 23% underwent confirmatory testing within 6 months of diagnosis. The use of confirmatory testing increased from 17.8% for men diagnosed in Q1 2016 to 31.7% for those diagnosed in Q1 2017 (p<.001). Sixty-eight percent of patients (n=382) had reassuring results of confirmatory testing. Rates of AS were significantly higher for patients with reassuring results (Figure 1); 73% (n=278) of patients with reassuring confirmatory tests remained on AS, compared to 51% (n=91) with non-reassuring results and 49% (n=927) with no confirmatory testing (p<.001). A larger share of patients >=65 years with a reassuring test remained on AS (80%) compared to those <65 (68%) (p=0.01).

CONCLUSIONS: The use of confirmatory testing is increasing among patients in Michigan diagnosed with favorable-risk prostate cancer. Moreover, rates of surveillance are higher among men with reassuring results, indicating a likely beneficial impact of these tests on clinical decision-making. Further research should evaluate the reasons for continued AS among men with non-reassuring confirmatory test results.

Source of Funding: Blue Cross Blue Shield of Michigan

---

*Favorable-risk prostate cancer: Any volume Gleason 3+3 disease or low volume Gleason 3+4, defined by 1-3 cores positive with no cores containing 3+4 with >50% cancer involvement

**Reassuring confirmatory result: MRI-PIRADS 1-2; Prolaris: <3% Probability of PCA Mortality; OncotypeDx: >80% Freedom from High Grade Disease or <=20% High Grade Disease; Decipher score <0.45; Prostate biopsy – biopsy no longer favorable risk